RxDoctor Payments Data

Melanie Hutchinson, DO

Family Medicine · Enid, OKNPI 1861872905

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Lilly USA, LLC at 29.5% of the total. Reporting peaked in 2022 at $156 and has fallen 78.0% since, to $34 in 2023. That places this record below the midpoint for family medicine clinicians in OK, where the typical reported total is $360.

$273in general payments, 2019–2025

Across 17 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$81
  • GSK$79
  • AstraZeneca$45
  • Novo Nordisk$41
  • Amgen$14
  • Novartis$13

What the payments were for

  • Food & beverage$273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$81
GSK4$79
AstraZeneca3$45
Novo Nordisk2$41
Amgen1$14
Novartis1$13

How this compares

$273 in reported general payments places this provider in the 45th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$76,480
Medicare patients
194
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban42$35,062
JanuviaSitagliptin Phosphate29$27,953
TrulicityDulaglutide17$26,852
EliquisApixaban33$21,915
FarxigaDapagliflozin Propanediol18$18,577
JardianceEmpagliflozin19$18,174
MounjaroTirzepatide14$16,681
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,317
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,902
Levothyroxine Sodium196$2,133
Atorvastatin Calcium169$1,902
Rosuvastatin Calcium90$1,799
Esomeprazole Magnesium19$1,752
Omeprazole105$1,740
SynthroidLevothyroxine Sodium16$1,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$81$43,53331 claims
AstraZenecaFarxiga, Breztri Aerosphere$45$27,89431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →